SIX WEEKS OF SOFOSBUVIR/ LEDIPASVIR (SOF/LDV) ARE SUFFICIENT TO TREAT ACUTE HEPATITIS C VIRUS GENOTYPE 1 MONOINFECTION: THE HEPNET ACUTE HCV IV STUDY

被引：5
|
作者：
Deterding, K. [1 ]
Spinner, C. [2 ]
Schott, E. [3 ]
Welzel, T. [4 ]
Gerken, G. [5 ]
Klinker, H. [6 ]
Spengler, U. [7 ]
Wiegand, J. [8 ]
zur Wiesch, J. Schulze [9 ]
Pathil, A. [10 ]
Cornberg, M. [1 ,11 ,12 ]
Umgelter, A. [2 ]
Zoellner, C. [3 ]
Zeuzem, S. [4 ]
von der Leyen, H. [13 ]
von Witzendorff, D. [11 ]
Manns, M. P. [1 ,11 ,12 ]
Wedemeyer, H. [1 ,11 ,12 ]
机构：
[1] Hannover Med Sch, Hannover, Germany
[2] Univ Hosp Klinikum Rechts Isar, Munich, Germany
[3] Charite Univ Med Berlin, Berlin, Germany
[4] Univ Hosp Frankfurt, Frankfurt, Germany
[5] Univ Hosp Essen, Essen, Germany
[6] Univ Wurzburg, Med Ctr, Wurzburg, Germany
[7] Univ Hosp Bonn, Bonn, Germany
[8] Univ Leipzig, Leipzig, Germany
[9] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[10] Univ Clin Heidelberg, Heidelberg, Germany
[11] German Liver Fdn, HepNet Study House, Hannover, Germany
[12] German Liver Fdn, German Ctr Infect Res, HepNet Study House, Hannover, Germany
[13] Hannover Clin Trial Ctr GmbH, Hannover, Germany
来源：
JOURNAL OF HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
10.1016/S0168-8278(16)00177-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LBO8
引用
收藏
页码：S211 / S211
页数：1
相关论文
共 50 条
  • [41] Sofosbuvir and Ribavirin for Six Weeks Is Not Effective Among People with Acute and Recently Acquired HCV Infection: The DARE-C II Study
    Martinello, Marianne
    Gane, Edward J.
    Hellard, Margaret
    Sasadeusz, Joe
    Shaw, David
    Petoumenos, Kathy
    Applegate, Tanya L.
    Grebely, Jason
    Maire, Laurence
    Marks, Philippa
    Cooper, David
    Dore, Gregory
    Matthews, Gail
    [J]. HEPATOLOGY, 2015, 62 : 741A - 742A
  • [42] The Impact of Concomitant Acid Reducing Therapy (ART) on Sustained Virologic Response (SVR-12) Among Genotype 1 Infected Chronic Hepatitis C (CHC) Patients Treated with Ledipasvir/Sofosbuvir (LDV/SOF) With or Without Ribavirin
    Spoutz, Patrick
    Schaefer, Monica
    Pandya, Prashant K.
    Patterson, Mark
    [J]. HEPATOLOGY, 2016, 64 : 477A - 478A
  • [43] Treatment of US Veterans with hepatitis C virus (HCV) genotype (GT) 1 infection: effectiveness of Ledipasvir/Sofosbuvir (Harvoni®) and Ombitasvir/Paritavir/Ritonavir/Dasubuvir (Viekira Pak®) regimens
    Issa, Danny
    Forte, Veda
    Tassone, Daniel
    Gilles, HoChong
    Solomon, Cynthia L.
    Owens, Stacy
    Obolewicz, Barbara
    Neuman, Douglas M.
    Fuchs, Michael
    [J]. HEPATOLOGY, 2016, 64 : 991A - 992A
  • [44] 100% SVR with 8 weeks of ledipasvir/sofosbuvir in HIV-infected Men with Acute HCV Infection: Results from the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals)
    Naggie, Susanna
    Fierer, Daniel S.
    Hughes, Michael
    Kim, Arthur Y.
    Luetkemeyer, Anne
    Vu, Vincent
    Roa, Jhoanna
    Brainard, Diana M.
    McHutchison, John G.
    Peters, Marion G.
    Kiser, Jennifer J.
    Marks, Kristen M.
    Chung, Raymond T.
    [J]. HEPATOLOGY, 2017, 66 : 113A - 113A
  • [45] Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/Sof) in Treatment-Experienced Cirrhotic Genotype 1 Patients With Chronic Hepatitis C (CHC): A Comparative Analysis of Gilead Sponsored Trials With 4 Real-World Cohorts (RWC)
    Flamm, Steven
    Modi, Apurva A.
    Pungpapong, Surakit
    Leise, Michael D.
    Aqel, Bashar
    Llewellyn, Joseph
    Williams, Laurie
    Natha, Macky
    Brainard, Diana
    Kreter, Bruce
    Kohli, Anita
    Wyles, David L.
    Lee, Yoori
    Reddy, K. R.
    Curry, Michael
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S1095 - S1095
  • [46] Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 hepatitis C virus-infected patients with severe renal impairment
    Gane, E. J.
    Lawitz, E.
    Landis, C. S.
    Maliakkal, B. J.
    Bonacini, M.
    Ortiz-Lasanta, G.
    Zhang, J.
    Mogalian, E.
    De-Oertel, S.
    Osinusi, A. O.
    Brainard, D. M.
    Mchutchison, J. G.
    Flamm, S. L.
    Gordon, S. C.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 43 - 43
  • [47] 100% SVR4 in Japanese Patients with Chronic Genotype 1 Hepatitis C Virus Infection Receiving Ledipasvir/Sofosbuvir Fixed Dose Combination for 12 Weeks: Results from a Multicenter Phase 3 Study
    Mizokami, Masashi
    Takehara, Tetsuo
    Yokosuka, Osamu
    Sakamoto, Naoya
    Korenaga, Masaaki
    Mochizuki, Hitoshi
    Nakane, Kunio
    Enomoto, Hirayuki
    Yanase, Mikio
    Toyoda, Hidenori
    Ikeda, Fusao
    Genda, Takuya
    Umemura, Takeji
    Yatsuhashi, Hiroshi
    Ide, Tatsuya
    Toda, Nobuo
    Nirei, Kazushige
    Ueno, Yoshiyuki
    Nishigaki, Yoichi
    Betular, Juan
    Gao, Bing
    Ishizaki, Akinobu
    Omote, Masa
    Pang, Phillip S.
    Knox, Steven J.
    Symonds, William T.
    McHutchison, John G.
    Izumi, Namiki
    Omata, Masao
    [J]. HEPATOLOGY, 2014, 60 : 1130A - 1130A
  • [48] Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group
    Tsuji, Keiji
    Kurosaki, Masayuki
    Itakura, Jun
    Mori, Nami
    Takaki, Shintaro
    Hasebe, Chitomi
    Akahane, Takehiro
    Joko, Kouji
    Yagisawa, Hitoshi
    Takezawa, Jirou
    Nakata, Ryou
    Kusakabe, Atsunori
    Kojima, Yuji
    Kimura, Hiroyuki
    Tamada, Takashi
    Kobashi, Haruhiko
    Mitsuda, Akeri
    Kondou, Masahiko
    Ogawa, Chikara
    Uchida, Yasushi
    Sohda, Tetsuro
    Narita, Ryouichi
    Izumi, Namiki
    [J]. JOURNAL OF GASTROENTEROLOGY, 2018, 53 (10) : 1142 - 1150
  • [49] Treatment with the single-tablet regimen ledipasvir/sofosbuvir for 12weeks results in 100% sustained virologic response in Japanese patients with chronic genotype-1 hepatitis C virus infection
    Mizokami, Masashi
    Takehara, Tetsuo
    Yokosuka, Osamu
    Sakamoto, Naoya
    Korenaga, Masaaki
    Mochizuki, Hitoshi
    Nakane, Kunio
    Enomoto, Hirayuki
    Yanase, Mikio
    Toyoda, Hidenori
    Ikeda, Fusao
    Genda, Takuya
    Umemura, Takeji
    Yatsuhashi, Hiroshi
    Ide, Tatsuya
    Toda, Nobuo
    Nirei, Kazushige
    Ueno, Yoshiyuki
    Nishigaki, Yoichi
    Betular, Juan
    Gao, Bing
    Ishizaki, Akinobu
    Omote, Masa
    Liu, Vivian
    Pang, Phillip S.
    Knox, Steven J.
    Symonds, William T.
    Mchutchison, John G.
    Izumi, Namiki
    Omata, Masao
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 372 - 373
  • [50] Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group
    Keiji Tsuji
    Masayuki Kurosaki
    Jun Itakura
    Nami Mori
    Shintaro Takaki
    Chitomi Hasebe
    Takehiro Akahane
    Kouji Joko
    Hitoshi Yagisawa
    Jirou Takezawa
    Ryou Nakata
    Atsunori Kusakabe
    Yuji Kojima
    Hiroyuki Kimura
    Takashi Tamada
    Haruhiko Kobashi
    Akeri Mitsuda
    Masahiko Kondou
    Chikara Ogawa
    Yasushi Uchida
    Tetsuro Sohda
    Ryouichi Narita
    Namiki Izumi
    [J]. Journal of Gastroenterology, 2018, 53 : 1142 - 1150
12345